Pfizer and BioNTech provided an update for their coronavirus vaccine that is currently in the late stages of development and testing.
After the caution seen in the prior period, short sellers seemed to find some focus. As of the most recently reported period, those sellers favored Pfizer, Exxon and Intel above all other…
24/7 has compiled a few biopharmaceutical names that have lagged the markets and recently have reported earnings. In a sense, the fundamentals have shown some light on these stocks, that they may…
Wednesday's top analyst upgrades and downgrades included Advanced Micro Devices, Amgen, DexCom, eBay, FireEye, Kraft Heinz, 3M, Pfizer, Seagate Technology, Sonos, Starbucks and T-Mobile.
Pfizer released a better than expected second-quarter earnings report and increased its guidance before the markets opened on Tuesday.
Chris Lange Pfizer and BioNTech made another big step in their fight against COVID-19 by initiating their late-stage study for their lead mRNA vaccine candidate.
As of the most recently reported period, short sellers still favored Exxon, Pfizer and Microsoft above all other Dow stocks.
Pfizer and BioNTech S.E. aim to begin delivering 300 million doses of their vaccine for COVID-19 in 2021, but in the meantime, these companies will get a nice payoff.
BioNTech is one of the leading companies in the race to a COVID-19 vaccine. With its shares up more than 160% year to date, it’s time to capitalize.
BioNTech and Pfizer are leading the pack of COVID-19 vaccine stocks as this collaboration came out with more positive news regarding their ongoing German Phase 1/2 study.
The number of COVID-19 cases continues to rise, which will only create more demand for coronavirus stocks. 24/7 Wall Street has picked out a few of the best and brightest that could…
Pfizer and BioNTech have progressed in their COVID-19 vaccine effort, according to the FDA. Two of the companies’ four coronavirus vaccine candidates received Fast Track Designation.
As of the most recently reported period, short sellers still favored Exxon, Pfizer and Microsoft above all other Dow stocks.
24/7 Wall St. has identified five defensive stocks that must greatly improve before they are deemed expensive or fully valued again.
Pfizer is among the current frontrunners for a COVID-19 vaccine, so why is its stock down 13% year to date? And why does one independent research firm say this stock could run…
Chris Lange 
